---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-026258"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2023-09-19T23:59:59+00:00"
generated_at: "2026-06-10T13:04:26.391275+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dyadic signs exclusive license deal with INZYMES for dairy enzymes; $0.6M upfront

## Summary
- Dyadic receives $0.6M upfront for development and licensing of Dapibus platform to INZYMES.
- Exclusive license targets non-animal dairy enzymes used in food production.
- Potential success fees, milestones, and royalties beyond upfront payment.
- Addressable alternative protein market cited at >$60B, growing to $190B by 2028.
- Deal builds on previous success producing animal-free casein proteins.

## SEC filing metadata
- accession: 0001437749-23-026258
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2023-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774923026258/0001437749-23-026258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774923026258/dyai20230918_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-026258
- JSON: https://secwatch.observer/filing/0001437749-23-026258.json
- Plain text: https://secwatch.observer/filing/0001437749-23-026258.txt

## Key facts
- Material Agreements
  DYADIC INTERNATIONAL INC entered into Development and Exclusive License Agreement with INZYMES ApS valued at upfront payment of $0.6 million (effective 2023-09-18).
  - Action: entry
  - Agreement: license
  - Counterparty: INZYMES ApS
  - Value: upfront payment of $0.6 million
  - Effective: 2023-09-18
  source text: On September 18, 2023, Dyadic International (USA), Inc., a subsidiary of Dyadic International, Inc. (“Dyadic” or the “Company”) signed a Development and Exclusive License Agreement (the “Agreement”) with INZYMES ApS (“INZYMES”), a Denmark corporation, to develop and commercialize certain non-animal dairy enzymes used in the production of food products using Dyadic’s proprietary DapibusTM platform.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213809/000143774923026258/0001437749-23-026258-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.